{"id":"NCT03201757","sponsor":"Alkermes, Inc.","briefTitle":"Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831","officialTitle":"A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-06-15","primaryCompletion":"2023-09-06","completion":"2023-09-06","firstPosted":"2017-06-28","resultsPosted":"2024-09-26","lastUpdate":"2024-09-26"},"enrollment":523,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia","Schizophreniform Disorder","Bipolar I Disorder"],"interventions":[{"type":"DRUG","name":"ALKS 3831","otherNames":[]}],"arms":[{"label":"ALKS 3831","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the long-term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder","primaryOutcome":{"measure":"Incidence of Adverse Events","timeFrame":"Up to 48 months","effectByArm":[{"arm":"ALKS 3831","deltaMin":314,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":85,"countries":["United States","Austria","Bulgaria","Ireland","Israel","Italy","Poland","Puerto Rico","Russia","Serbia","South Korea","Ukraine","United Kingdom"]},"refs":{"pmids":["39630083"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":35,"n":523},"commonTop":["Weight increased","Headache","Anxiety","Insomnia","Nausea"]}}